Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
Purpose The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in RET-dependent malignancies, and selective RET inhibitors (...
Main Authors: | Jessica Lee, Vivek Subbiah, Shuang Liu, Jason Roszik, David Hong, Funda Meric-Bernstam, John Heymach, Ramona Dadu, Kenneth Hess, Le Huang, Aparna Hegde, Alexander Y Andreev-Drakhlin, Maria Cabanillas, Mimi I Hu, Naifa L Busaidy, Steven I Sherman, Elizabeth G Grubbs, Siraj M Ali, Yasir Y Elamin, George R Simon, George R Blumenschein, Jr, Vassiliki A Papadimitrakopoulou |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | ESMO Open |
Online Access: | https://esmoopen.bmj.com/content/5/5/e000799.full |
Similar Items
-
Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
by: Naifa Lamki Busaidy, et al.
Published: (2012-01-01) -
Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
by: Maria E. Cabanillas, et al.
Published: (2011-01-01) -
Whole Genome Sequencing in Cancer Clinics
by: Ken Chen, et al.
Published: (2015-01-01) -
Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design
by: Anastasios Dimou, et al.
Published: (2014-06-01) -
RETsENZIYa
by: - -
Published: (2015-12-01)